Phase I dose-escalation study of EZN-2208 (PEG-SN38), a novel conjugate of poly(ethylene) glycol and SN38, administered weekly in patients with advanced cancer. [electronic resource]
Producer: 20130801Description: 1499-506 p. digitalISSN:- 1432-0843
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents -- administration & dosage
- Camptothecin -- administration & dosage
- Data Interpretation, Statistical
- Dose-Response Relationship, Drug
- Drug Administration Schedule
- Female
- Humans
- Infusions, Intravenous
- Irinotecan
- Male
- Middle Aged
- Neoplasms -- drug therapy
- Polyethylene Glycols -- administration & dosage
- Prodrugs -- administration & dosage
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.